Clinical trials
HIV 2 Infection clinical trials
Below are recruiting hiv 2 infection clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06730555Recruiting
HIV and hepatitis C testing for people who inject drugs
This study works with syringe service programs to see if offering opt-out HIV and hepatitis C testing helps more people get screened and connected to care. It focuses on programs that do not already offer this testing and are in high-need areas.
Miami, FloridaAges 18 years+ - NCT06810934RecruitingPhase 1/Phase 2
New COVID-19 vaccine study for those with prior mRNA vaccines
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
Los Angeles, CaliforniaAges 40–64 - NCT06920628RecruitingPhase 1
Brain scan study for long COVID neurological symptoms
This study uses a special PET scan to look at brain inflammation in people with neurological symptoms after COVID-19. It aims to understand how inflammation might be linked to ongoing problems like brain fog or memory issues.
Bethesda, MarylandAges 18–70 - NCT07031063RecruitingPhase 4
HIV treatment study for people starting therapy
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Mexico City, AzcapotzalcoAges 18 years+ - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07226323Recruiting
WeCare for mental health and medication adherence in South Africa
This trial tests a counselling program called WeCare to help men who have sex with men in Johannesburg stick to their HIV or PrEP medication and manage depression symptoms. It is designed for those who are struggling with adherence or have unsuppressed HIV.
JohannesburgAges 18 years+ - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT00187512Recruiting
Study of how HIV treatment changes outcomes over time
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
San Francisco, CaliforniaAges 18 years+ - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT04984772Enrolling by invitation
HIV and hepatitis B coinfection follow-up study in Europe
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Ages 16 years+ - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT05136703Recruiting
Study depression treatment effects in people living with HIV
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
Coral Gables, FloridaAges 18 years+ - NCT03174977RecruitingEarly Phase 1
How HIV medicine moves through the body on MRI scans
This early study measures how raltegravir (an HIV medicine) spreads in the body using a special scan called PET/MR. It may help doctors better understand how to deliver and monitor HIV treatment, even though it focuses on measuring drug behavior rather than curing HIV.
San Francisco, CaliforniaAges 18 years+ - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT07181486RecruitingPhase 1
Safety study of a vaginal gel for healthy women
This trial tests a gel placed in the vagina to see if it is safe. Healthy women with regular periods who have a steady partner may join.
San Francisco, CaliforniaAges 18–45 - NCT07030075Recruiting
Flu and respiratory infection study in Lusaka
This study looks at flu-like symptoms and other respiratory infections in adults in Lusaka, Zambia. It aims to understand how these infections affect people with and without HIV, and may help improve care.
Lusaka, Lusaka ProvinceAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT06691321Recruiting
Caspofungin for Pneumocystis Pneumonia in HIV patients
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Mexico City, TlalpanAges 18–60 - NCT06843902RecruitingPhase 2
Improving heart blood flow in women with HIV
This study is testing a medication that may help improve blood flow to the heart in women with HIV who also have diabetes, kidney disease, or protein in their urine. You would need to have a heart scan that shows low blood flow and not be taking certain diabetes drugs.
Boston, MassachusettsAges 45–75
Hear when a new HIV 2 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv 2 infection?
- Yes. Clin2 currently lists 143 recruiting hiv 2 infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv 2 infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv 2 infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.